SCHEMBL5539633

SCHEMBL5539633

[CH2]c1oc(-c2cccc(F)c2)nc1C

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.48
SLC9A1 P19634 1/20 0.45
NOTUM Q6P988 2/20 0.45
TP53 P04637 1/20 0.43
HPN P05981 1/20 0.43
GUSB P08236 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
VSIR Q9H7M9 2/20 0.41
GRM5 P41594 1/20 0.40
UTRN P46939 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539637 0.83 MAOB (0.50) MAOBSLC9A1NOTUMTP53HPN
SCHEMBL5543447 0.81 SLC9A1 (0.48) MAOBSLC9A1NOTUMTP53HPN
SCHEMBL5540607 0.81 NPC1 (0.50) MAOBSLC9A1NOTUMTP53GUSB
SCHEMBL5536086 0.79 GAA (0.50) KDM4EGAA
SCHEMBL5541453 0.74 ADORA2A (0.43) MAOBSLC9A1NOTUMTRPM8MGAM
SCHEMBL13393581 0.71 TRPM8 (0.60) MAOBNOTUMTP53GUSBTRPM8
SCHEMBL9286817 0.71 ADORA2A (0.50) KDM4EMGAMGAASIMGAM2
SCHEMBL5543906 0.71 TRPM8 (0.41) MAOBNOTUMTP53GUSBL3MBTL1
SCHEMBL12163868 0.71 KDM4E (0.50) MAOBSLC9A1HPNKDM4E
SCHEMBL4830084 0.71 KDM4E (0.50) MAOBSLC9A1NOTUMHPNKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885SLC9A1 2413/4885NOTUM 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.